Cargando…
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
BACKGROUND: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. METHODS: We conducted...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847406/ https://www.ncbi.nlm.nih.gov/pubmed/33554155 http://dx.doi.org/10.1016/j.medj.2021.01.005 |
_version_ | 1783644927523028992 |
---|---|
author | Pradenas, Edwards Trinité, Benjamin Urrea, Víctor Marfil, Silvia Ávila-Nieto, Carlos Rodríguez de la Concepción, María Luisa Tarrés-Freixas, Ferran Pérez-Yanes, Silvia Rovirosa, Carla Ainsua-Enrich, Erola Rodon, Jordi Vergara-Alert, Júlia Segalés, Joaquim Guallar, Victor Valencia, Alfonso Izquierdo-Useros, Nuria Paredes, Roger Mateu, Lourdes Chamorro, Anna Massanella, Marta Carrillo, Jorge Clotet, Bonaventura Blanco, Julià |
author_facet | Pradenas, Edwards Trinité, Benjamin Urrea, Víctor Marfil, Silvia Ávila-Nieto, Carlos Rodríguez de la Concepción, María Luisa Tarrés-Freixas, Ferran Pérez-Yanes, Silvia Rovirosa, Carla Ainsua-Enrich, Erola Rodon, Jordi Vergara-Alert, Júlia Segalés, Joaquim Guallar, Victor Valencia, Alfonso Izquierdo-Useros, Nuria Paredes, Roger Mateu, Lourdes Chamorro, Anna Massanella, Marta Carrillo, Jorge Clotet, Bonaventura Blanco, Julià |
author_sort | Pradenas, Edwards |
collection | PubMed |
description | BACKGROUND: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. METHODS: We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for >6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by ELISA against the S2 subunit, the receptor binding domain (RBD), and the nucleoprotein (NP). Statistical analyses were carried out using mixed-effects models. FINDINGS: We found that individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted 6 months after symptom onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which decreased following a 2-phase pattern, with an initial rapid decline that significantly slowed after day 80. Despite this initial decay, neutralizing activity at 6 months remained higher among hospitalized individuals compared to mild symptomatic. The slow decline in neutralizing activity at mid-term contrasted with the steep slope of anti-RBD, S2, or NP antibody titers, all of them showing a constant decline over the follow-up period. CONCLUSIONS: Our results reinforce the hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage. FUNDING: This study was funded by 10.13039/501100016387Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III (grant nos. PI17/01518 and PI18/01332 to J.C.), CERCA Programme/Generalitat de Catalunya2017 SGR 252, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript. E.P. was supported by a doctoral grant from the National Agency for Research and Development of Chile (ANID; 72180406). C.A.-N. was supported by a doctoral grant from Generalitat de Catalunya and Fons Social Europeu (FI). S.P.-Y. was supported by 10.13039/501100011850Fundación Canaria Doctor Manuel Morales and 10.13039/100015528Universidad de La Laguna. |
format | Online Article Text |
id | pubmed-7847406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78474062021-02-01 Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes Pradenas, Edwards Trinité, Benjamin Urrea, Víctor Marfil, Silvia Ávila-Nieto, Carlos Rodríguez de la Concepción, María Luisa Tarrés-Freixas, Ferran Pérez-Yanes, Silvia Rovirosa, Carla Ainsua-Enrich, Erola Rodon, Jordi Vergara-Alert, Júlia Segalés, Joaquim Guallar, Victor Valencia, Alfonso Izquierdo-Useros, Nuria Paredes, Roger Mateu, Lourdes Chamorro, Anna Massanella, Marta Carrillo, Jorge Clotet, Bonaventura Blanco, Julià Med (N Y) Clinical and Translational Report BACKGROUND: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. METHODS: We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for >6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by ELISA against the S2 subunit, the receptor binding domain (RBD), and the nucleoprotein (NP). Statistical analyses were carried out using mixed-effects models. FINDINGS: We found that individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted 6 months after symptom onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which decreased following a 2-phase pattern, with an initial rapid decline that significantly slowed after day 80. Despite this initial decay, neutralizing activity at 6 months remained higher among hospitalized individuals compared to mild symptomatic. The slow decline in neutralizing activity at mid-term contrasted with the steep slope of anti-RBD, S2, or NP antibody titers, all of them showing a constant decline over the follow-up period. CONCLUSIONS: Our results reinforce the hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage. FUNDING: This study was funded by 10.13039/501100016387Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III (grant nos. PI17/01518 and PI18/01332 to J.C.), CERCA Programme/Generalitat de Catalunya2017 SGR 252, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript. E.P. was supported by a doctoral grant from the National Agency for Research and Development of Chile (ANID; 72180406). C.A.-N. was supported by a doctoral grant from Generalitat de Catalunya and Fons Social Europeu (FI). S.P.-Y. was supported by 10.13039/501100011850Fundación Canaria Doctor Manuel Morales and 10.13039/100015528Universidad de La Laguna. Elsevier Inc. 2021-03-12 2021-01-31 /pmc/articles/PMC7847406/ /pubmed/33554155 http://dx.doi.org/10.1016/j.medj.2021.01.005 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Clinical and Translational Report Pradenas, Edwards Trinité, Benjamin Urrea, Víctor Marfil, Silvia Ávila-Nieto, Carlos Rodríguez de la Concepción, María Luisa Tarrés-Freixas, Ferran Pérez-Yanes, Silvia Rovirosa, Carla Ainsua-Enrich, Erola Rodon, Jordi Vergara-Alert, Júlia Segalés, Joaquim Guallar, Victor Valencia, Alfonso Izquierdo-Useros, Nuria Paredes, Roger Mateu, Lourdes Chamorro, Anna Massanella, Marta Carrillo, Jorge Clotet, Bonaventura Blanco, Julià Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes |
title | Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes |
title_full | Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes |
title_fullStr | Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes |
title_full_unstemmed | Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes |
title_short | Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes |
title_sort | stable neutralizing antibody levels 6 months after mild and severe covid-19 episodes |
topic | Clinical and Translational Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847406/ https://www.ncbi.nlm.nih.gov/pubmed/33554155 http://dx.doi.org/10.1016/j.medj.2021.01.005 |
work_keys_str_mv | AT pradenasedwards stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT trinitebenjamin stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT urreavictor stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT marfilsilvia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT avilanietocarlos stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT rodriguezdelaconcepcionmarialuisa stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT tarresfreixasferran stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT perezyanessilvia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT rovirosacarla stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT ainsuaenricherola stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT rodonjordi stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT vergaraalertjulia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT segalesjoaquim stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT guallarvictor stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT valenciaalfonso stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT izquierdouserosnuria stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT paredesroger stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT mateulourdes stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT chamorroanna stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT massanellamarta stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT carrillojorge stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT clotetbonaventura stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes AT blancojulia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes |